SCHEMBL4826175

SCHEMBL4826175

N=Nc1ccccc1S(=O)(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
MYC P01106 1/20 0.40
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TTR P02766 2/20 0.39
FABP4 P15090 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
MAPK14 Q16539 1/20 0.39
NR4A1 P22736 1/20 0.38
SUMO2 P61956 3/20 0.37
SUMO1 P63165 3/20 0.37
SENP7 Q9BQF6 3/20 0.37
SENP2 Q9HC62 3/20 0.37
SENP1 Q9P0U3 3/20 0.37
SENP3 Q9H4L4 2/20 0.37
CTRB1 P17538 1/20 0.36
POLB P06746 3/20 0.35
CYP2D6 P10635 1/20 0.35
MPL P40238 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790419 0.82 CYP1A2 (0.50) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL3870157 0.80 MYC (0.41) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL10788346 0.80 CYP1A2 (0.45) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL2225465 0.78 CYP1A2 (0.40) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL1808795 0.78 MYC (0.44) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL343357 0.78 MYC (0.44) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL8914222 0.78 CYP1A2 (0.40) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL27983206 0.78 CA2 (0.50) CDK2
SCHEMBL892272 0.77 MYC (0.43) CYP1A2MYCTSHRSMN1; SMN2TTR
SCHEMBL7205854 0.77 SUMO2 (0.43) CYP1A2MYCTSHRSMN1; SMN2TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0348344-B1 Azo dyes CIBA GEIGY AG (CH) 1993-12-29 EP claimed
EP-0253788-B1 A METHOD OF PREPARING 5-AMINO SALICYCLIC ACID Nobel Kemi AB (SE) 1992-01-29 EP claimed
US-20170275595-A1 Bionanomaterials and Their Synthesis UNIVERSITY OF SOUTH CAROLINA 2017-09-28 US disclosed
US-9683218-B2 Bionanomaterials and their synthesis UNIVERSITY OF SOUTH CAROLINA (US) 2017-06-20 US disclosed
US-20170096643-A9 Bionanomaterials and Their Synthesis UNIVERSITY OF SOUTH CAROLINA (US) 2017-04-06 US disclosed
US-8975312-B2 Color indicating epoxy resins and methods thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-03-10 US disclosed
US-20130143303-A1 Bionanomaterials and Their Synthesis UNIVERSITY OF SOUTH CAROLINA (US) 2013-06-06 US disclosed
US-20130096234-A1 COLOR INDICATING EPOXY RESINS AND METHODS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-18 US disclosed
US-7820426-B2 Bionanomaterials and their synthesis UNIVERSITY OF SOUTH CAROLINA (US) 2010-10-26 US disclosed
US-20090029441-A1 BIONANOMATERIALS AND THEIR SYNTHESIS UNIVERSITY OF SOUTH CAROLINA (US) 2009-01-29 US disclosed
US-7396369-B2 2,3-disubstituted primary para-phenylenediamines and process for oxidation dyeing of keratin fibers L'OREAL S.A. (FR) 2008-07-08 US disclosed
US-20070011823-A1 Novel 2,3-disubstituted primary para-phenylenediamines and process for oxidation dyeing of keratin fibers L'OREAL S.A. (FR) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070011823-A1 Novel 2,3-disubstituted primary para-phenylenediamines and process for oxidation dyeing of keratin fibers KRT18, VIM, CDC73 CYP1A2 763/4885MYC 1630/4885TSHR 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.